Comparative Pharmacology
Head-to-head clinical analysis: BRILINTA versus TICAGRELOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRILINTA versus TICAGRELOR.
BRILINTA vs TICAGRELOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible, direct-acting P2Y12 platelet receptor antagonist that inhibits ADP-mediated platelet aggregation.
Ticagrelor is a reversible, direct-acting P2Y12 receptor antagonist that inhibits ADP-induced platelet aggregation.
Acute coronary syndrome: Loading dose 180 mg orally, then 90 mg orally twice daily. Maintenance therapy for patients with ACS: 90 mg twice daily. For patients with prior MI and high risk for atherothrombotic events: 60 mg orally twice daily.
Loading dose: 180 mg orally once. Maintenance: 90 mg orally twice daily.
None Documented
None Documented
Ticagrelor: ~7 hours (range 6–8.5 h). AR-C124910XX: ~9 hours. Clinical context: Twice-daily dosing achieves steady state within 2–3 days with minimal accumulation.
Clinical Note
moderateTicagrelor + Tranilast
"Ticagrelor may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateTicagrelor + Resveratrol
"Ticagrelor may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateTicagrelor + Nimesulide
"Ticagrelor may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateTicagrelor + Alprostadil
"Ticagrelor may increase the anticoagulant activities of Alprostadil."
The terminal elimination half-life of ticagrelor is approximately 7 hours, and for its active metabolite (AR-C124910XX) it is about 9 hours. This supports twice-daily dosing, achieving steady state within 2–3 days.
Approximately 58% of the total radioactivity is excreted in feces via biliary route, and 26% in urine. Unchanged ticagrelor is minimal in urine (<1%) and feces (<1%). The major metabolite (AR-C124910XX) is also eliminated via feces and urine.
Approximately 58% of the dose is eliminated via feces and 26% via urine. The parent drug and its active metabolite are primarily excreted in feces via biliary secretion, with renal excretion playing a minor role.
Category C
Category A/B
P2Y12 Inhibitor
P2Y12 Inhibitor